GH Research Stock Forecast
NASDAQ: GHRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
GHRS analyst consensus
Consensus (9 analysts)
none
Avg. price target
$42.89+109.73%
- Strong buy 2
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering GH Research (2026-10-08), 9 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $42.89, with a high estimate of $65.00 and a low estimate of $38.00. The average target implies upside of 109.7% from the current price of $20.45.
The spread between the highest and lowest targets is 71.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for GHRS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 22% |
| Buy | 7 | 78% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $38.00 | +85.82% |
| Average target | $42.89 | +109.73% |
| High target | $65.00 | +217.85% |